Adverse Drug Reactions and Pharmacovigilance of Herbal Medicines

Stephens' Detection and Evaluation of Adverse Drug Reactions: Principles and Practice, Sixth Edition

Volumn , Issue , 2012, Pages 645-683

  Barnes, Joanne ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Adverse drug reactions; Herbal medicines; Pharmacovigilance

Indexed keywords

EID: 84886202785     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470975053.ch15     Document Type: Chapter

References (176)

1. World Health Organization. WHO Guidelines on Safety Monitoring of Herbal Medicines in Pharmacovigilance Systems. Geneva: World Health Organization, 2004.
2. The European Parliament and the Council of the European Union. Directive 2004/24/EC of the European Parliament and of the Council of 31 March 2004, amending, as regards traditional herbal medicinal products, Directive 2001/83/EC on the Community code relating to medicinal products for human use. Off J Eur Union 2004; L136: 85-90.
3. The Medicines Act. London: The Stationery Office, 1968. 4. World Health Organization. WHO Traditional Medicine Strategy 2002-2005. Geneva: World Health Organization, 2002.
4. Barnes J, Anderson LA, Phillipson JD. Herbal Medicines. 3rd edition. London: Pharmaceutical Press, 2007.
5. De Los Reyes GC, Koda RT. Determining hyperforin and hypericin content in eight brands of St John's wort. Am J Health Syst Pharm 2002; 59: 545-7.
6. Harkey MR, Henderson GL, GershwinME, Stern JS, Hackman RM.Variability in commercial ginseng products: an analysis of 25 preparations. Am J Clin Nutr 2001; 73: 1101-6.
7. Gilroy CM, Steiner JF, Byers T, Shapiro H, Georgian W. Echinacea and truth in labelling. Arch Intern Med. 2003; 163: 699-704.
8. Loew D, Kaszkin M. Approaching the problem of bioequivalence of herbal medicinal products. Phytother Res 2002; 16: 705-11.
9. World Health Organization. National Policy on Traditional Medicine and Regulation of Herbal Medicines. Report of a WHO global survey. Geneva: World Health Organization, 2005.
10. Herbal Medicine Regulatory Working Group. Recommendations on the Regulation of Herbal Practitioners in the UK. Foundation for Integrated Health. London: Department of Health, 19 September 2003. http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4070170.
11. European Commission. Directive 2001/83/EC. Brussels: European Commission, 2001.
12. The Medicines (Aristolochia and Mu Tong) (Prohibition) Order 2001. (SI 2001/1841). London: The Stationery Office, 2001.
13. Medicines and Healthcare Products Regulatory Agency (MHRA). Guidance on use of HMPC monographs to demonstrate safety and traditional use. December 2007. http://www.mhra.gov.uk/home/groups/esherbal/documents/websiteresources/con2033554.pdf.
14. Medicines and Healthcare Products Regulatory Agency (MHRA). Traditional Herbal Medicines Registration Scheme. http://www.mhra.gov.uk/Howweregulate/Medicines/Herbalmedicines/Placingaherbalmedicineonthe UKmarket/TraditionalHerbalMedicinesRegistrationScheme/index.htm.
15. Medicines and Healthcare Products Regulatory Agency (MHRA). Press release: Poor practice in the unlicensed herbal sector: MHRA warns the public to be vigilant, 4 March 2008. http://www.mhra.gov.uk/NewsCentre/Pressreleases/CON014134.
16. European Commission. Strategy to better protect public health by strengthening and rationalising EU pharmacovigilance: public consultation on legislative proposals. Brussels: European Commission; 200. http://ec. europa.eu/enterprise/sectors/pharmaceuticals/files/pharmacovigilance/docs/public-consultation_12-2007_en. pdf.
17. European Commission. Proposal for a Directive of the European Parliament and of the Council amending, as regards pharmacovigilance, Directive 2001/83/EC on the Community code relating to medicinal products for human use {SEC(2008) 2670}{SEC(2008) 2671} COM(2008) 665 final - 2008/0260 (COD). Brussels; 2008 (updated 2008 10 December; cited 2009 8 June); available from: http://eur-lex. europa.eu/LexUriServ/LexUriServ.do?uri=COM:2008:0665:FIN:EN:PDF.
18. European Commission. Proposal for a regulation of the European Parliament and of the Council amending, as regards pharmacovigilance of medicinal products for human use, Regulation (EC) No 726/2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency {SEC(2008) 2670}{SEC(2008) 2671} COM(2008) 664 final - 2008/0257 (COD).Brussels; 2008 (updated 2008 10 December; cited 2009 8 June); available from: http://eur-lex. europa.eu/LexUriServ/LexUriServ.do?uri=COM:2008:0664:FIN:EN:PDF.
19. European Commission Enterprise and Industry. The EU pharmacovigilance system, 2009. http://ec.europa.eu/enterprise/pharmaceuticals/pharmacovigilance/pharmacovigilance_en.htm.
20. Henderson L, Yue QY, Bergquist C, Gerden B, Arlett P. St John'swort (Hypericum perforatum): drug interactions and clinical outcomes. Br J Clin Pharmacol 2002; 54: 349-56.
21. Adcock H. Medicines Control Agency proposes ban for kava-containing products. Pharm J 2002; 269: 128.
22. De Smet PAGM, Keller K, Hansel R, ChanderRF. Toxicological outlook on quality assurance of herbal remedies. In: De Smet PAGM, Keller K, Hansel R, Chander RF, editors. Adverse Effects of Herbal Drugs. Vol 1. Berlin: Springer-Verlag, 1992.
23. Busse W. The significance of quality for efficacy and safety of herbal medicinal products. Drug Inf J 2000; 34: 15-23.
24. De Smet PAGM. Health risks of herbal remedies. Drug Saf 1995; 13(2): 81-93.
25. Therapeutic Goods Act. 1989. http://www.comlaw.gov.au/comlaw/Legislation/ActCompilation1.nsf/0/904216A352A2D532CA257538007ED985/file/TherapeuticGoods1989_WD02.pdf.
26. Therapeutic Goods Regulations 1990. http://www.comlaw.gov.au/ComLaw/Management.nsf/lookupindexpagesbyid/IP200400127?OpenDocument.
27. Australian Regulatory Guidelines for Complementary Medicines (ARGCM). http://www.tga.gov.au/docs/html/argcm.htm.
28. Medicines Act. 1981. http://www.legislation.govt.nz/.
29. Dietary Supplement Regulations (1985). SR 1985/208. http://www.legislation.govt.nz/.
30. Food Act. 1981. http://www.legislation.govt.nz/.
31. Medsafe and New Zealand Food Safety Authority. Letter to organisations involved in the manufacture, distribution and advertising of dietary supplements in New Zealand. 2007. http://www.medsafe.govt.nz/.
32. Anonymous. Postponement of theANZTPAestablishment project. 2007.Available from: http://www.anztpa.org.
33. Food and Drug Administration. Department of Health and Human Services. Dietary Supplement Health and EducationAct of 1994. Public Law103-417, 103rdCongress. 1994. http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/ucm148003.htm.
34. Office of Dietary Supplements. National Institutes of Health. Dietary Supplements. Background information. http://ods.od.nih.gov/factsheets/DietarySupplements.asp.
35. Dietary Supplement and Nonprescription Drug Consumer Protection Act (2006). GovTrack.us. S. 3546-109th Congress. http://www.govtrack.us/congress/bill.xpd?bill=s109-3546.
36. Food and Drug Administration. Department of Health and Human Services. Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements; Final Rule. Federal Register: June 25, 2007; 72(121); 34751-34958. 2007. http://www.fda.gov/Food/DietarySupplements/GuidanceComplianceRegulatoryInformation/RegulationsLaws/ucm079496.htm.
37. Natural Health Products Regulations. PC 2003-847. Canada Gazette 2003: 137(13). http://gazette.gc.ca/archives/p2/2003/2003-06-18/html/sor-dors196-eng.html.
38. Natural Health Products Directorate. Natural Health Products Directorate Guidance Document. http://www.hcsc.gc.ca/dhp-mps/prodnatur/legislation/docs/license-licence_guide_tc-tm-eng.php.
39. Thomas KJ, Nicholl JP, Coleman P. Use and expenditure on complementary medicine in England: a population based survey. Complement Ther Med 2001; 9: 2-11.
40. MacLennan AH, Wilson DH, Taylor AW. The escalating cost and prevalence of alternative medicine. Prev Med 2002; 35: 166-73.
41. Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Van Rompay M, Kessler RC. Trends in alternative medicine use in the United States, 1990-1997: results of a national follow-up survey. JAMA 1998; 280(18): 1569-75.
42. Barnes J, Mills SY, Abbot NC, Willoughby M, Ernst E. Different standards for reporting ADRs to herbal remedies and conventional OTC medicines: face-to-face interviews with 515 users of herbal remedies. Br J Clin Pharmacol 1998; 45(5): 496-500.
43. Giveon SM, Liberman N, Klang S, Kahan E. Are people who use "natural drugs" aware of their potentially harmful side effects and reporting to family physician? Patient Educ Couns 2004; 53: 5-11.
44. Gulian C, Barnes J, Francis S-A. Types and preferred sources of information concerning herbal medicinal products: face-to-face interviews with users of herbal medicinal products [abstract]. Int J Pharm Pract 2002; 10(Suppl): R33.
45. Vickers AJ, Rees RW, Robin A. Advice given by health food stores: is it clinically safe? J R Coll Phys Lond 1998; 32(5): 426-8.
46. Quinn CG, Waterman P. A comparison of the teaching of herbal medicine in the UK and Europe. University of Strathclyde, 1997.
47. Medicines and Healthcare Products Regulatory Agency (MHRA). More evidence of poor professional practice in the herbal medicine sector. 20 June 2008. http://www.mhra.gov.uk/Howweregulate/Medicines/Herbalmedicines/HerbalSafetyNews/Currentsafetyissues/CON018174.
48. Teng L, Shaw D, Barnes J. Practice of traditional Chinese herbal medicine shops in central London. Phytochem Lett 2008; 1(2): 94-8.
49. Bensoussan A, Myers SP, Carlton A-L. Risks associated with the practice of traditional Chinese medicine. An Australian study. Arch Fam Med 2000; 9: 1071-8.
50. Medicines and Healthcare Products Regulatory Agency (MHRA). Press release: Chinese clinic rapped for making false claims 2007. http://www.mhra.gov.uk/NewsCentre/Pressreleases/CON2031848.
51. Barnes J, Abbot NC. Experiences with complementary medicines: a survey of community pharmacists. Int J Pharm Pract 2007; 15: 167-75.
52. Cockayne NL, Duguid M, Shenfield G. Health professionals rarely record history of complementary and alternative medicines. Br J Clin Pharmacol 2004; 59(2): 254-8.
53. Constable S, Ham A, Pirmohamed M. Herbal medicines and acute medical emergency admissions to hospital. Br J Clin Pharmacol 2007; 63(2): 247-8.
54. Smith CFP, Ernst E, Ewings P, Myers P, Smith C. Co-ingestion of herbal medicines and warfarin. Br J Gen Pract 2004; 54(503): 439-41.
55. Barnes J. Pharmacovigilance of herbal medicines. A UK perspective. Drug Saf 2003; 26(12): 829-51. 57. Ernst E, De Smet PA, Shaw D, Murray V. Traditional remedies and the "test of time". Eur J Clin Pharmacol 1998; 54(2): 99-100.
56. Ernst E, De Smet PA, Shaw D, Murray V. Traditional remedies and the "test of time". Eur J Clin Pharmacol 1998; 54(2): 99-100.
57. World Health Organization. WHO policy perspectives on medicines. Pharmacovigilance: ensuring the safe use of medicines. Geneva: World Health Organization, 2004.
58. Nicholson T. Complementary and alternative medicines (including traditional Maori treatments) used by presenters to an emergency department in New Zealand: a survey of prevalence and toxicity. NZ Med J 2006; 119(1233): U1954.
59. Barnes J. An examination of the role of the pharmacist in the safe, effective and appropriate use of complementary medicines. PhD thesis, University of London, 2001.
60. Charrois TL, Hill RL, Vu D, Foster BC, Boon HS, Cramer K, Vohra S. Community identification of natural health product-drug interactions. Ann Pharmacother 2007; 41(7): 1124-9.
61. Hamre HJ, Witt CM, Glockmann A, Tröger W, Willich SN, Kiene H. Use and safety of anthroposophic medications in chronic disease. A 2-year prospective analysis. Drug Saf 2006; 29(12): 1173-89.
62. MacPherson H, Liu B. The safety of Chinese herbal medicine: a pilot study for a national survey. J Alt Comp Med 2005; 11(4): 617-26.
63. Chan TY, Chan AY, Critchley JA. Hospital admissions due to adverse reactions to Chinese herbal medicines. J Trop Med Hyg 1992; 95(4): 296-8.
64. Aronson JK. Plant poisons. In: Cook G, Zumla A, editors. Manson's Tropical Diseases. 22nd edition. London: Harcourt International; 2009.
65. Woodfield R. Senecio species in unlicensed herbal remedies. London: Medicines Control Agency; 2002. 67. The Medicines for Human Use (Kava-Kava) (Prohibition) Order 2002. (SI2002/3170). London: The Stationery Office, 2002.
66. Pittler MH, Ernst E. Kava extract versus placebo for treating anxiety. The Cochrane Database of Systematic Reviews 2003, Issue 1 Art No: CD003383, 2003.
67. Schulze J, Raasch W, Siegers C-P. Toxicity of kava pyrones, drug safety and precautions-a case study. Phytomedicine 2003; 10: 68-73.
68. Stickel F, Baumüller HM, Seitz K, Vasilakis D, Seitz G, Seitz HK, Schuppan D. Hepatitis induced by kava (Piper methysticum rhizoma). J Hepatol 2003; 39: 62-7.
69. Gow PJ, Connelly NJ, Hill RL, Crowley P, Angus PW. Fatal fulminant hepatic failure induced by a natural therapy containing kava. Med J Aust 2003; 178: 442-3.
70. Clough AR, Bailie RS, Currie B. Liver function test abnormalities in users of aqueous kava extracts. J Toxicol Clin Toxicol 2003; 41(6): 821-9.
71. Russmann S, Barguil Y, Cabalion P, Kritsanida M, Duhet D, Lauterburg BH. Hepatic injury due to traditional aqueous extracts of kava root in New Caledonia. Eur J Gastroenterol Hepatol 2003; 15: 1033-6.
72. Vigibase. WHO Adverse Reactions Database. Uppsala Monitoring Centre, 2006.
73. Medicines and Healthcare Products Regulatory Agency (MHRA). Black Cohosh. UK Public Assessment Report 2006. http://www.mhra.gov.uk/home/groups/es-herbal/documents/websiteresources/con2024279.pdf.
74. Medicines and Healthcare Products Regulatory Agency (MHRA). Black cohosh (Cimicifuga racemosa)-risk of liver problems. 19 July 2006. http://www.mhra.gov.uk/Howweregulate/Medicines/Herbalmedicines/HerbalSafetyNews/Currentsafetyissues/CON2024131.
75. European Medicines Agency (EMEA). EMEA public statement on herbal medicinal products containing Cimicifuga racemosa rhizome (black cohosh, root)-serious hepatic reactions. European Medicines Agency, 18 July 2006. Ref: EMEA/269259/2006; 2006.
76. De Smet PAGM. Safety concerns about kava not unique. Lancet 2002; 360: 1336.
77. Benninger J, Schneider HT, Schuppan D, Kirchner T, Hahn EG. Acute hepatitis induced by greater celandine (Chelidonium majus). Gastroenterology 1999; 117: 1234-7.
78. Stickel F, Pöschl G, Seitz HK, Waldherr R, Hahn EG, Schuppan D. Acute hepatitis induced by greater celandine (Chelidonium majus). Scand J Gastroenterol 2003; 5: 565-8.
79. Vigibase. WHO Adverse Reactions Database. Uppsala Monitoring Centre, 2005.
80. Therapeutic Goods Administration. Greater celandine (Chelidonium majus). Proposed labelling advisory statement for the herb greater celandine (Chelidonium majus). 7 August 2003. http://www.tga.gov.au/docs/html/celandine.htm.
81. Medicines and Healthcare Products Regulatory Agency (MHRA). Polygonum multiflorum and liver reactions. April 2006. http://www.mhra.gov.uk/Howweregulate/Medicines/Herbalmedicines/HerbalSafetyNews/Currentsafetyissues/CON2023590.
82. But P-H, Tomlinson B, Lee K-L. Hepatitis related to the Chinese medicine Shou-wu-pian manufactured from Polygonum multiflorum. Vet Human Toxicol 1996; 38(4): 280-2.
83. Mazzanti G, Battinelli L, Daniele C, Mastoianni CM, Lichtner M, Coletta S, Costantini S. New case of acute hepatitis following the consumption of Shou Wu Pian, a Chinese herbal product derived from Polygonum multiflorum. Ann Intern Med 2004; 140(7): W30.
84. Park G-H, Mann SP, Hgu MC. Acute hepatitis induced by Shou-Wu-Pian, a herbal product derived from Polygonum multiflorum. J Gastroenterol Hepatol 2001; 16: 115-7.
85. Panis B, Wong DR, Hooymans PM, De Smet PAGM, Rosias PPR. Recurrent toxic hepatitis in a Caucasian girl related to the use of Shou-Wu-Pian, a Chinese herbal preparation. J Pediatr Gastroenterol Nutr 2005; 41(2): 256-8.
86. Cardenas A, Restrepo JC, Sierra F, Correa G. Acute hepatitis due to Shen-Min. A herbal product derived from Polygonum multiflorum. J Clin Gastroenterol 2006; 40(7): 629-32.
87. European Medicines Agency (EMEA). Herbal Medicinal Products Working Party. Position paper on the risks associated with the use of herbal products containing Aristolochia species. 31 October 2000. http://www.emea.europa.eu/pdfs/human/hmpc/002300en.pdf.
88. International Agency for Research on Cancer (IARC). IARC monographs on the evaluation of carcinogenic risk of chemicals to humans. Volume 82. Lyons: IARC Press, 2002.
89. Cosyns J-P, Jadoul M, Squifflet J-P, de Plaen J-F, Ferluga D, Van Ypersele De Strihou C. Chinese herbs nephropathy: a clue to Balkan endemic nephropathy. Kidney Int 1994; 45: 1680-8.
90. Nortier JL, Martinez MC, Schmeiser HH, Arlt VM, Bieler CA, Petein M, Depierreux MF, De Pauw L, Abramowicz D, Vereerstraeten P, Vanherweghem JL. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med 2000; 342: 1686-92.
91. Vanherweghem JL, Depierreux M, Tielemans C, Abramowicz D, Dratwa M, Jadoul M, Richard C, Vandervelde D, Verbeelen D, Vanhaelen-Fastre R, Vanhaelen M, Dratwa M, Richard C, Vandervelde D, Verbeelen D, Jadoul M. Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet 1993; 341: 387-91.
92. VanYpersele C, Vanherweghem J-L. The tragic paradigm of Chinese herb nephropathy. Nephrol Dial Transplant 1995; 10: 157-60. 680 ADVERSE DRUG REACTIONS AND PHARMACOVIGILANCE OF HERBAL MEDICINES.
93. Cosyns J-P, Jadoul M, Squifflet J-P, Wese F-X, Van Ypersele De Strihou C. Urothelial lesions in Chinese-herb nephropathy. Am J Kidney Dis 1999; 33: 1011-7.
94. Lord GM, Tagore R, Cook T, Gower P, Pusey CD. Nephropathy caused by Chinese herbs in the UK. Lancet 1999; 354: 481-2.
95. Lord G, Cook T, Arit V, Schmeiser H, Williams G, Pusey C. Urothelial malignant disease and Chinese herbal nephropathy. Lancet 2001; 358: 1515-6.
96. Charvill A. Investigation of formulated Traditional Chinese Medicines (TCM) and raw herbs for the presence of Aristolochia species. British Pharmaceutical Conference Science Proceedings, 2001. London. Pharmaceutical Press. 2001: 295.
97. Medicines and Healthcare Products Regulatory Agency (MHRA). Warning: dangerous acids found in Chinese medicines. 29 November 2007. http://www.mhra.gov.uk/NewsCentre/Pressreleases/CON2033198.
98. Medicines and Healthcare Products Regulatory Agency (MHRA). MHRA warns against Traditional Chinese Medicines found to contain Aristolochia 2007: http://www.mhra.gov.uk/Howweregulate/Medicines/Herbalmedicines/HerbalSafetyNews/Currentsafetyissues/CON2031938.
99. Gold LS, Slone TH. Aristolochic acid, an herbal carcinogen, sold on the Web after FDA alert. N Engl J Med 2003; 349: 1576-7.
100. Medicines and Healthcare Products Regulatory Agency (MHRA). Burns from Psoralea corylifolia fruit in traditional herbal medicines. 1 February 2005. http://www.mhra.gov.uk/Howweregulate/Medicines/Herbalmedicines/HerbalSafetyNews/Currentsafetyissues/CON2018005.
101. Schempp CM, Winghofer B, Müller K, Schulte-Mönting J, Mannel M, Schöpf E, Simon JC. Effect of oral administration of Hypericum perforatum extract (St John's wort) on skin erythema and pigementation induced by UV-B, UV-A, visible light and solar simulated radiation. Phytother Res 2003; 17: 141-6.
102. Schempp CM, Lüdtke R, Winghofer B, Simon JC. Effect of topical application of Hypericum perforatum extract (St John's wort) on skin sensitivity to solar simulated radiation. Photodermatol Photoimmunol Photomed 2000; 16: 125-8.
103. Sadraei H, Ghannadi A, Takei-Bavani M. Effects of Zataria multiflora and Carum carvi essential oils and hydroalcoholic extracts of Passiflora incarnata, Berberis integerrima and Crocus sativus on rat isolated uterus contractions. Int J Aromather 2003; 13(2/3): 121-7.
104. Barnes J, Anderson LA, Phillipson JD. St. John's wort (Hypericum perforatum L.): a review of its chemistry, pharmacology and clinical properties. J Pharm Pharmacol 2001; 53: 583-600.
105. Barnes J, Anderson LA, Phillipson JD. Herbal interactions. Pharm J 2003; 270: 118-21.
106. Williamson EM. Drug interactions between herbal and prescription medicines. Drug Saf 2003; 26(15): 1075-92.
107. Baxter K, editor. Stockley's Drug Interactions. 8th edition. London: Pharmaceutical Press; 2007.
108. Halil M, Cankurtaran M, Yavuz BB, Ozkayar N, Ulger Z, Dede DS, Shorbagi A, Buyukasik Y, Haznedaroglu IC, Arogul S. No alteration in the PFA-100 in vitro bleeding time induced by the Ginkgo biloba special extract, Egb 761, in elderly patents with mild cognitive impairment. Blood Coagul Fibrinolysis 2005; 16: 349-53.
109. Gaus W, Westendorf J, Diebow R, Kieser M. Identification of adverse drug reactions by evaluation of a prescription database, demonstrated for "risk of bleeding". Methods Inf Med 2005; 44: 697-703.
110. Director-General of Health. Herbal products containing undeclared sildenafil and sibutramine. Health warning issued under section 98 of the Medicines Act 1981. Media release, 17 April 2007. http://www.medsafe.govt.nz/hot/Herbal/SildenafilandSubtramineApr07/DGStatement.asp.
111. Mannel M. Drug interactions with St John's wort. Drug Saf 2004; 27(11): 773-97.
112. Anonymous. Interaction between warfarin and cranberry juice: new advice. Curr Probl Pharmacovig 2004; 30: 10.
113. De Smet PAGM. Health risks of herbal remedies: an update. Clin Pharmacol Ther 2004; 76(1): 1-17.
114. Biessels GJ, Vermeij FH, Leijten FS. Epileptische aanval na drinken van Sterrenmixthee: intoxicatie met Japanse steranijs. [Epileptic seizure after a cup of tea: intoxication with Japanese star anise.] Ned Tijdschr Geneeskd 2002; 146: 808-11.
115. Ize-Ludlow D, Ragone S, Bruck IS, Bernstein JN, Duchowny M, Garcia Pena BM. Neurotoxicities in infants seen with the consumption of star anise tea. Pediatrics 2004; 114(5): e653-6.
116. Tu G, editor. Pharmacopoeia of the People's Republic of China (English edition, 2000. Beijing: Chemical Industry Press, 2005.
117. Huang WF, Wen KC, Hsiao ML. Adulteration by synthetic therapeutic substances of traditional Chinese medicines in Taiwan. J Clin Pharmacol 1997; 37: 344-50.
118. Koh H-L, Woo S-O. Chinese proprietary medicine in Singapore: regulatory control of toxic heavy metals and undeclared drugs. Drug Saf 2000; 23: 351-62.
119. Saper RB, Kales SN, Paquin J, Burns MJ, Eisenberg DM, Davis RB, Phillips RS. Heavy metal content of Ayurvedic herbal medicine products. JAMA 2004; 292: 2868-73.
120. Lau KK, Lai CK, Chan AYW. Phenytoin poisoning after using Chinese proprietarymedicines. Hum Exp Toxicol 2000; 19: 385-6.
121. Anonymous. Hypoglycaemia following the use of Chinese herbal medicine Xiaoke Wan. Curr Probl Pharmacovigilance 2001; 27: 8.
122. Anonymous. Reminder: safety of traditional Chinese medicines and herbal remedies. Curr Probl Pharmacovig 2004; 30: 10.
123. Wu M-S. Multiple tubular dysfunction induced by mixed Chinese herbal medicines containing cadmium. Nephrol Dial Transplant 1996; 11: 867-70.
124. Kew J, Morris C, Aihie A, Fysh R, Jones S, Brooks D. Arsenic and mercury intoxication due to Indian ethnic remedies. BMJ 1993; 306: 506-7.
125. Waller PC, Evans SJW. A model for the future conduct of pharmacovigilance. Pharmacoepidemiol Drug Saf 2003; 12: 17-29.
126. De Smet PAGM. An introduction to herbal pharmacovigilance. In: De Smet PAGM, Keller K, Hänsel R, Chander RF, editors. Adverse Effects of Herbal Drugs, Vol 3. Berlin: Springer-Verlag, 1997.
127. Chen Y. Safety monitoring of traditional Chinese medicines in China. Proceedings of the International Symposium on the Pharmacovigilance of Herbal Medicines: Current State and Future Directions; Royal College of Obstetricians and Gynaecologists, Regents Park, London, 28 April 2006. Drug Saf 2006; 29(4): 352.
128. Dodoo ANO, Appiah-Danquah A. Safety of herbal medicines: the practitioners' view. Proceedings of the International Symposium on the Pharmacovigilance of Herbal Medicines: Current State and Future Directions; Royal College of Obstetricians and Gynaecologists, Regents Park, London, 28 April 2006. Drug Saf 2006; 29(4): 350.
129. Dodoo ANO, Appiah-Danquah A, Gysana-Lutterodt M, Duweiejua M. Safety monitoring of herbal medicines in Ghana: challenges and opportunities. Proceedings of the International Symposium on the Pharmacovigilance of Herbal Medicines: Current State and Future Directions; Royal College of Obstetricians and Gynaecologists, Regents Park, London, 28 April 2006. Drug Saf 2006; 29(4): 352.
130. Farah MH, Edwards R, Lindquist M, Leon C, Shaw D. International monitoring of adverse health effects associated with herbal medicines. Pharmacoepidemiol Drug Saf 2000; 9: 105-12.
131. Uppsala Monitoring Centre-World Health Organization Collaborating Centre for International Drug Monitoring. Guidelines for herbal ATC classification. Uppsala: Uppsala Monitoring Centre, 2004.
132. Uppsala Monitoring Centre-World Health Organization Collaborating Centre for International Drug Monitoring. Accepted scientific names of therapeutic plants and their synonyms. Uppsala: Uppsala Monitoring Centre, 2005.
133. Farah MH, Olsson S, Bate J, Lindquist M, Edwards R, Simmonds MS, Leon C, de Boer HJ, Thulin M. Botanical nomenclature in pharmacovigilance and a recommendation for standardisation. Drug Saf 2006; 29(11): 1023-9.
134. Anonymous. Extension of the yellow card scheme to unlicensed herbal remedies. Curr Probl Pharmacovig 1996; 22: 10.
135. Shaw D, Leon C, Kolev S, Murray V. Traditional remedies and food supplements: a 5-year toxicological study (1991-1995). Drug Saf 1997; 17(5): 342-56.
136. Anonymous. Extension of the yellow card scheme to pharmacists. Curr Probl Pharmacovig 1997; 23: 3.
137. Anonymous. Patients able to report ADRs via NHS Direct. Pharm J 2003; 270: 608.
138. Raine J. The new European regulatory framework: implications for safety and pharmacovigilance of herbal medicines. International Conference on Pharmacovigilance of Herbal Medicines: Current State and Future Directions. London, 2006.
139. Gogolak VV. The effect of backgrounds in safety analysis: the impact of comparison cases on what you see. Pharmacoepidemiol Drug Saf 2003; 12: 249-52.
140. Bate A, Ericsson J, Farah M. International data mining for signals of herbal ADRs. Proceedings of the International Symposium on the Pharmacovigilance of Herbal Medicines: Current State and Future Directions; Royal College of Obstetricians and Gynaecologists, Regents Park, London, 28 April 2006. Drug Saf 2006; 29(4): 353.
141. Ahn B-M. Herbal preparation-induced liver injury. Korean J Gastroenterol 2004; 44: 113-25.
142. Van Grootheest K, de Graaf L, de Jong-van den Gerg LTW. Consumer adverse drug reaction reporting: a new step in pharmacovigilance? Drug Saf 2003; 26(4): 211-7.
143. Green CF, Mottram DR, Raval D, Proudlove C, Randall C. Community pharmacists' attitudes to adverse drug reaction reporting. Int J Pharm Pract 1999; 7: 92-9. 682 ADVERSE DRUG REACTIONS AND PHARMACOVIGILANCE OF HERBAL MEDICINES.
144. Wingfield J, Walmsley J, Norman C. What do Boots pharmacists know about yellow card reporting of adverse drug reactions? Pharm J 2002; 269: 109-10.
145. Biscoe R, Houghton JE, Woods FJ. An audit of the level of encouragement given by medicines information pharmacists to enquirers of suspected adverse drug reactions to complete a yellow card report: perspectives in patient safety [abstract]. 28th UK Medicines Information Conference Proceedings. Chester, UK, 2002.
146. Davis S, Coulson R. Community pharmacist reporting of suspected ADRs: (1) the first year of the yellow card demonstration scheme. Pharm J 1999; 263: 786-8.
147. InmanWHW, Weber JCP. TheUnited Kingdom. In: InmanWHW, editor. Monitoring forDrug Safety.Lancaster: MTP Press, 1986: 13-47.
148. Barnes J, Aggarwal AM. Spontaneous reporting of ADRs associated with herbal medicines: final results of a cross-sectional survey of national pharmacovigilance centres. Proceedings of the International Symposium on the Pharmacovigilance of Herbal Medicines: Current State and FutureDirections; Royal College of Obstetricians and Gynaecologists, Regents Park, London, 28 April 2006. Drug Saf 2006; 29(4): 359.
149. Broughton AL. Adverse event reporting by herbal practitioners: the National Institute of Medical Herbalists yellow card reporting scheme. Proceedings of the International Symposium on the Pharmacovigilance of Herbal Medicines: Current State and Future Directions; Royal College of Obstetricians and Gynaecologists, Regents Park, London, 28 April 2006. Drug Saf 2006; 29(4): 348.
150. Booker T. The Register of Chinese Herbal Medicine 'yellow card scheme'. Proceedings of the International Symposium on the Pharmacovigilance of Herbal Medicines: Current State and Future Directions; Royal College of Obstetricians and Gynaecologists, Regents Park, London, 28 April 2006. Drug Saf 2006; 29(4): 349.
151. Mills S. The ESCOP perspective on ADRs and ADR reporting. Proceedings of the International Symposium on the Pharmacovigilance of Herbal Medicines: Current State and FutureDirections; Royal College of Obstetricians and Gynaecologists, Regents Park, London, 28 April 2006. Drug Saf 2006; 29(4): 350.
152. British HerbalMedicine Association. Code of good practice: unlicensed herbal remedies. Bournemouth: British Herbal Medicine Association, 1997.
153. Shakir SAW. PEM in the UK. In: Mann RD, Andrews EB, editors. Pharmacovigilance. Chichester: John Wiley & Sons, Ltd, 2002: 333-44.
154. Layton D, Sinclair HK, Bond CM, Hannaford PC, Shakir SAW. Pharmacovigilance of over-the-counter products based in community pharmacy: methodological issues from pilot work conducted in Hampshire and Grampian, UK. Pharmacoepidemiol Drug Saf 2002; 11: 503-13.
155. Sinclair HK, Bond CM, Hannaford PC. Pharmacovigilance of over-the-counter products based in community pharmacy: a feasible option? Pharmacoepidemiol Drug Saf 1999; 8: 479-91.
156. Aggarwal AM, Barnes J. A pilot study of community-pharmacy-based pharmacovigilance of an over-thecounter herbal medicine ginkgo (Ginkgo biloba): methodological issues from work in progress. Proceedings of the International Symposium on the Pharmacovigilance of Herbal Medicines: Current State and Future Directions; Royal College of Obstetricians and Gynaecologists, Regents Park, London, 28 April 2006. Drug Saf 2006; 29(4): 358.
157. Layton D, Denham A, Whitelegg ME, Shaw D, Barnes J, Brown D, Lewith G, Shakir SAW. Methodology of a feasibility study to assess the application of prescription event monitoring (PEM) to monitor the safety of herbal medicines. Proceedings of the International Symposium on the Pharmacovigilance of Herbal Medicines: Current State and Future Directions; Royal College of Obstetricians and Gynaecologists, Regents Park, London, 28 April 2006. Drug Saf 2006; 29(4): 355.
158. Chuang CH, Doyle P, Wang JD, Chang PJ, Lai JN, Chen PC. Herbal medicines used during the first trimester and major congenital malformations. An analysis of data from a pregnancy cohort study. Drug Saf 2006; 29(6): 537-48.
159. Gallo M, Sarkar M, Au W, Pietrzak K, Comas B, Smith M, Jaeger TV, Einarson A, Koren G. Pregnancy outcome following gestational exposure to Echinacea: a prospective controlled study. Arch Intern Med 2000; 160: 3141-3.
160. Gibson PS, Powrie R, Star J. Herbal and alternative medicine use during pregnancy: a cross-sectional survey. Obstet Gynecol 2001; 97(Suppl 1): S44-5.
161. Nordeng H, Havnen GC. Use of herbal drugs in pregnancy: a survey among 400 Norwegian women. Pharmacoepidemiol Drug Saf 2004; 13: 371-80.
162. Tsui B, Dennehy CE, Tsourounis C. A survey of dietary supplement use during pregnancy at an academic medical center. Am J Obst Gynecol 2001; 185: 433-7.
163. Strom BL. How should one perform pharmacoepidemiology studies? Choosing among the available alternatives. In: Strom BL, editor. Pharmacoepidemiology. 3rd edition. Chichester: John Wiley & Sons, Ltd, 2000: 401-13.
164. Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C; CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT statement. Ann InternMed 2006; 144: 364-7.
165. Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C; CONSORT Group. Recommendations for reporting randomized controlled trials of herbal interventions: explanation and elaboration. J Clin Epidemiol 2006; 59: 1134-49.
166. Dy GK, Bekele L, Hanson LJ, Furth A, Mandrekar S, Sloan JA, Adjei AA. Complementary and alternative medicine use by patients enrolled onto phase I clinical trials. J Clin Oncol 2004; 22(23): 4810-5.
167. Moher DG, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann Intern Med 2004; 134: 657-62.
168. Ioannidis JPA, Evans SJW, Gotsche PC, O'Neill RT, Altman DG, Schulz K, Moher D; CONSORT Group. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann InternMed 2004; 141: 781-8.
169. Wu TX, Li YP, Bian ZX, Li TQ, Li J, Dagenais S, MoherD; CONSORT forTCMGroup. Consolidated standards for reporting trials of traditional Chinese medicine (CONSORT for TCM). Chin J Evid Based Med 2007; 7: 625-30.
170. Berry DC, Knapp PR, Raynor DK. Is 15% very common: informing people about the risks of medication side effects. Int J Pharm Pract 2002; 10: 145-51.
171. Berry DC, Raynor DK, Knapp PR, Bersellini E. Patients' understanding of risk associated with medication use: impact of European Commission guidelines and other risk scales. Drug Saf 2003; 26(1): 1-11.
172. Edwards IR, Olsson S. WHO programme: global monitoring. In: Mann RD, Andrews EB, editors. Pharmacovigilance. Chichester: John Wiley & Sons, Ltd, 2002: 169-82.
173. Department of Health. A vision for pharmacy in the new NHS. London: Department of Health, 2003.
174. KellyWN, Arellano FM, Barnes J, BergmanU, Edwards RI, FernandezAM, Freedman SB, Goldsmith DI, Huang KA, Jones JK, McLeay R, MooreN, Stather RH, Trenque T, TroutmanWG, van Puijenbroek E, Williams F, Wise RP; International Society for Pharmacoepidemiology; International Society of Pharmacovigilance. Guidelines for submitting adverse event reports for publication. Drug Saf 2007; 30(5): 367-73.
175. Pirmohamed M, Park BK. Genetic susceptibility to ADRs. Trends Pharmacol Sci 2001; 22(6): 298-305.
176. Pirmohamed M. Pharmacogenomics and herbal medicines. Proceedings of the International Symposium on the Pharmacovigilance of Herbal Medicines: Current State and Future Directions; Royal College of Obstetricians and Gynaecologists, Regents Park, London, 28 April 2006. Drug Saf 2006; 29(4): 356.